EPCAM and cancer: Enriched CTCs were then analyzed in three steps by flow cytometry: (i) removing dead cells, (ii) isolation of CD45(−) PanCK(+) cells as CTCs, and (iii) analysis of CTCs producing CD90, CD133, EpCAM, or vimentin, which are proteins associated with cancer progression (Fig. 1C).